Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ligand Pharmaceuticals (LGND) EBT (2016 - 2025)

Ligand Pharmaceuticals' EBT history spans 16 years, with the latest figure at $56.8 million for Q4 2025.

  • For Q4 2025, EBT rose 244.85% year-over-year to $56.8 million; the TTM value through Dec 2025 reached $159.0 million, up 6212.95%, while the annual FY2025 figure was $159.0 million, 6212.95% up from the prior year.
  • EBT for Q4 2025 was $56.8 million at Ligand Pharmaceuticals, down from $141.1 million in the prior quarter.
  • Across five years, EBT topped out at $141.1 million in Q3 2025 and bottomed at -$65.4 million in Q2 2024.
  • The 5-year median for EBT is $11.8 million (2022), against an average of $16.7 million.
  • The largest annual shift saw EBT tumbled 2162.13% in 2024 before it soared 2326.49% in 2025.
  • A 5-year view of EBT shows it stood at $17.9 million in 2021, then soared by 35.0% to $24.1 million in 2022, then fell by 29.18% to $17.1 million in 2023, then plummeted by 329.28% to -$39.2 million in 2024, then skyrocketed by 244.85% to $56.8 million in 2025.
  • Per Business Quant, the three most recent readings for LGND's EBT are $56.8 million (Q4 2025), $141.1 million (Q3 2025), and $11.2 million (Q2 2025).